Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more
Synaptogenix Inc (SNPX) - Total Assets
Latest total assets as of June 2025: $19.79 Million USD
Based on the latest financial reports, Synaptogenix Inc (SNPX) holds total assets worth $19.79 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Synaptogenix Inc - Total Assets Trend (2018–2024)
This chart illustrates how Synaptogenix Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Synaptogenix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Synaptogenix Inc's total assets of $19.79 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synaptogenix Inc's current assets represent 99.9% of total assets in 2024, unchanged from 99.9% in 2018.
- Cash Position: Cash and equivalents constituted 99.6% of total assets in 2024, up from 97.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Synaptogenix Inc Competitors by Total Assets
Key competitors of Synaptogenix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Synaptogenix Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Synaptogenix Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Synaptogenix Inc is currently not profitable relative to its asset base.
Synaptogenix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 20.51 | 2.98 | 22.40 |
| Quick Ratio | 20.51 | 2.98 | 22.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.82 Million | $ 18.47 Million | $ 27.83 Million |
Synaptogenix Inc - Advanced Valuation Insights
This section examines the relationship between Synaptogenix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -43.0% |
| Total Assets | $17.73 Million |
| Market Capitalization | $8.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synaptogenix Inc's assets below their book value (0.45 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Synaptogenix Inc's assets decreased by 43.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Synaptogenix Inc (2018–2024)
The table below shows the annual total assets of Synaptogenix Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.73 Million | -43.00% |
| 2023-12-31 | $31.11 Million | -19.41% |
| 2022-12-31 | $38.61 Million | +8.68% |
| 2021-12-31 | $35.52 Million | +426.21% |
| 2020-12-31 | $6.75 Million | -62.28% |
| 2019-12-31 | $17.90 Million | -39.28% |
| 2018-12-31 | $29.48 Million | -- |